{"schema_version":"secwatch.filing_event.v1","accession":"0001638833-22-000002","form_type":"8-K","ticker":"SGRY","cik":"0001638833","company_name":"Surgery Partners, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.508118+00:00","generated_at":"2026-06-27T19:27:14.954918+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Surgery Partners reaffirms 2021/2022 guidance, appoints David Doherty as CFO","bullets":["David Doherty appointed EVP & CFO effective Feb 1, 2022, succeeding Thomas Cowhey who resigns Jan 31, 2022.","Doherty receives $515K base salary, 75% target bonus, $200K restricted stock award, $800K annual equity target.","Company reaffirms 2021 Adjusted EBITDA guidance of $325M-$330M and revenue growth 19%-21% vs 2020.","Completed $185M in three December 2021 acquisitions at ~8.5x 2022E EBITDA; reaffirms 2022 Adj EBITDA min $370M.","Cowhey to remain through Feb 2022; his unvested PSUs and restricted stock vest in March 2022 as agreed."],"urls":{"canonical":"https://secwatch.observer/filing/0001638833-22-000002","json":"https://secwatch.observer/filing/0001638833-22-000002.json","markdown":"https://secwatch.observer/filing/0001638833-22-000002.md","text":"https://secwatch.observer/filing/0001638833-22-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638833/000163883322000002/0001638833-22-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638833/000163883322000002/sgry-20220105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:27:14.954918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07458f3d7d","claim":"David T. Doherty was appointed as Executive Vice President and Chief Financial Officer at Surgery Partners, Inc..","evidence_excerpt":"On January 10, 2022, the Company announced the appointment of David T. Doherty to serve as Executive Vice President and Chief Financial Officer of the Company, effective as of February 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638833/000163883322000002/0001638833-22-000002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}